Literature DB >> 10544150

Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5.

Y Isaka1, A Sato, S Miki, S Kawauchi, H Sakaida, T Hori, T Uchiyama, A Adachi, M Hayami, T Fujiwara, O Yoshie.   

Abstract

HIV-2 GH-1 is a molecular clone derived from an AIDS patient from Ghana. In contrast to the prototypic molecular clone ROD, GH-1 exhibits a narrow range of target cell specificity. By an infectious assay using HeLa-CD4 cells stably transfected with an HIV-1 LTR-beta-galactosidase reporter gene and transiently expressing various cloned chemokine receptors, we have examined the coreceptor usage of GH-1. In contrast to ROD, which uses principally CXCR4, GH-1 was found to use mainly if not exclusively CCR5 but not CXCR4. The distinct coreceptor usage of these two molecular clones allowed us to further map the region of gp120 that is important for the coreceptor specificity. By constructing a series of chimeric viruses between GH-1 and ROD, we have demonstrated that the C-terminal half of the V3 loop region of gp120 determines the differential coreceptor usage between GH-1 and ROD, and only a few amino acid differences in this region appear to be able to shift the specificity between CCR5 and CXCR4. Notably, the shift in the coreceptor usage from CCR5 to CXCR4 is associated with an increase in the net positive charge in the V3 region. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544150     DOI: 10.1006/viro.1999.0006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

3.  Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient.

Authors:  Jori Symons; Linos Vandekerckhove; Gero Hütter; Annemarie M J Wensing; Petra M van Ham; Steven G Deeks; Monique Nijhuis
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

4.  Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Authors:  Takahiro Seki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Shigeru Miki; Chiaki Wakasa-Morimoto; Erika Akihisa; Koichiro Nakahara; Masanori Kobayashi; Mark R Underwood; Akihiko Sato; Tamio Fujiwara; Tomokazu Yoshinaga
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  Impact of viral factors on very early in vivo replication profiles in simian immunodeficiency virus SIVagm-infected African green monkeys.

Authors:  Ivona Pandrea; Christopher Kornfeld; Mickael J-Y Ploquin; Cristian Apetrei; Abdourahmane Faye; Pierre Rouquet; Pierre Roques; François Simon; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin; Ousmane M Diop
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.

Authors:  Diana M Brainard; William G Tharp; Elva Granado; Nicholas Miller; Alicja K Trocha; Xiang-Hui Ren; Brian Conrad; Ernest F Terwilliger; Richard Wyatt; Bruce D Walker; Mark C Poznansky
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Authors:  Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark R Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

8.  Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors.

Authors:  Stefan Pöhlmann; Carl Davis; Silke Meister; George J Leslie; Claas Otto; Jacqueline D Reeves; Bridget A Puffer; Armin Papkalla; Mandy Krumbiegel; Andrea Marzi; Steffen Lorenz; Jan Münch; Robert W Doms; Frank Kirchhoff
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.

Authors:  Renate R König; Egbert Flory; Stefanie Steidl; Jeanette Neumann; Cheick Coulibaly; Edgar Holznagel; Silke Holzammer; Stephen Norley; Klaus Cichutek
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.

Authors:  George Lin; Andrea Bertolotti-Ciarlet; Beth Haggarty; Josephine Romano; Katrina M Nolan; George J Leslie; Andrea P-O Jordan; Chih-chin Huang; Peter D Kwong; Robert W Doms; James A Hoxie
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.